標題: Titlebook: Cancer Immunotherapy; Paradigms, Practice Tyler J. Curiel Book 2013 Springer Science+Business Media New York 2013 Anti-tumor immunity.Canc [打印本頁] 作者: papertrans 時間: 2025-3-21 19:17
書目名稱Cancer Immunotherapy影響因子(影響力)
書目名稱Cancer Immunotherapy影響因子(影響力)學(xué)科排名
書目名稱Cancer Immunotherapy網(wǎng)絡(luò)公開度
書目名稱Cancer Immunotherapy網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cancer Immunotherapy被引頻次
書目名稱Cancer Immunotherapy被引頻次學(xué)科排名
書目名稱Cancer Immunotherapy年度引用
書目名稱Cancer Immunotherapy年度引用學(xué)科排名
書目名稱Cancer Immunotherapy讀者反饋
書目名稱Cancer Immunotherapy讀者反饋學(xué)科排名
作者: Blanch 時間: 2025-3-21 22:20
T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment. In this chapter, we review and summarize current knowledge regarding the function, interactions, and prognostic significance of each of these populations, as well as their dependence upon one another within the tumor microenvironment.作者: dominant 時間: 2025-3-22 04:08 作者: NEEDY 時間: 2025-3-22 06:28
Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Conceptsthe lymphoid organs where they present the antigen and control the activation of B and T cells, the mediators of specific immunity. DC-based immunotherapy is explored worldwide in clinical vaccination trials with cancer patients aiming to induce or augment an antitumor immune response. The majority 作者: 打火石 時間: 2025-3-22 09:42
Peptide and Protein-Based Cancer Vaccinesons and early mobilization of the immune system. In cancer, tumor cells have evolved to overcome immune surveillance or grow in the presence of exhausted immune cells. However, the identification of tumor-infiltrating lymphocytes as good prognostic indicator of increased survival in cancer disease 1作者: 圓柱 時間: 2025-3-22 14:56
Antigen Targeting to Dendritic Cells for Cancer Immunotherapyigrate to the draining lymph nodes where they can induce an antigen-specific T cell response. A promising strategy to induce a potent, specific, and lasting anti-tumor response is to target tumor antigens to DC in vivo. This represents a clinically generally applicable and cost-effective approach to作者: 圓柱 時間: 2025-3-22 18:34
Cytokines in the Treatment of Cancertokines classified by their receptor usage. The effects of individual cytokines on immunity depend on several factors, including the local cytokine concentration, the pattern of cytokine receptor expression, and the integration of multiple signaling pathways in responding immune cells. Cytokines hav作者: fringe 時間: 2025-3-22 23:59 作者: CRUE 時間: 2025-3-23 02:33
Managing Regulatory T Cells to Improve Cancer Immunotherapynt cancer histologies. Cancer Tregs not only are capable of impeding endogenous protective anti-tumor immunity from optimal functioning but are also capable of impeding the efficacy of anti-cancer immunotherapy. Tumor-associated Tregs represent heterogeneous populations, differing by their origins a作者: Override 時間: 2025-3-23 07:29 作者: inconceivable 時間: 2025-3-23 13:20 作者: Middle-Ear 時間: 2025-3-23 15:46 作者: 草率女 時間: 2025-3-23 20:33
Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokdes a broad overview of additional approaches not covered in specific book chapters. Some areas are nonetheless quite advanced, such as the use of TLR agonists in clinical trials, and some have received FDA approvals such as BCG to treat bladder cancer and the IMiD lenalidomide to treat multiple mye作者: gain631 時間: 2025-3-24 02:02
Monitoring Antigen-Specific Responses in Clinical Trials of Cancer Immunotherapyative parameters of immune function affords the opportunity to identify endpoints that correlate with, or predict clinical benefit and define the requirements for effective therapy. This chapter discusses structural and functional methods to assess both monoclonal and polyclonal antigen-specific T c作者: DEVIL 時間: 2025-3-24 05:59 作者: AVOID 時間: 2025-3-24 08:15 作者: RENIN 時間: 2025-3-24 11:23
International Political Economy Seriesimprove T cell function and tumor targeting. However many of these strategies come with a price and re-introduce toxicities including death in rare cases. This chapter will outline the development of tumor-specific lymphocyte therapies, highlighting successes and difficulties and discussing potentia作者: JOT 時間: 2025-3-24 15:39 作者: Lime石灰 時間: 2025-3-24 19:31 作者: 不近人情 時間: 2025-3-25 00:17
Modeling the Kinetics of the Immune Responseunctional blockade, differentiation blockade, altering trafficking, differentiation diversion, or raising the threshold of anti-cancer effector cells for Treg-mediated regulation. Several clinical trials have shown the feasibility and relative safety of managing Tregs in human cancer, although treat作者: Axillary 時間: 2025-3-25 05:41
Historical Perspectives and Current Trends in Cancer Immunotherapy of autoimmunity. These newer understandings caused thinking to evolve and advance. Our rapidly increasing understanding of antitumor immunity and how it can be thwarted has led to new approaches to tumor immunotherapy with great promise to be much more successful than prior generations of approache作者: Paraplegia 時間: 2025-3-25 10:03
Adoptive T Cell Transferimprove T cell function and tumor targeting. However many of these strategies come with a price and re-introduce toxicities including death in rare cases. This chapter will outline the development of tumor-specific lymphocyte therapies, highlighting successes and difficulties and discussing potentia作者: ELATE 時間: 2025-3-25 13:25
Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel ConceptsAlthough the evidence on clinical responses is still scarce, expectations are high because the clinical responses that are induced are often long lasting. To improve clinical responses of DC vaccination further, a number of variables are already being tested in clinical trials, including DC maturati作者: 違反 時間: 2025-3-25 19:01
Peptide and Protein-Based Cancer Vaccinesent knowledge on the promise and pitfalls of defined antigen vaccination strategies for cancer based on synthetic peptides and proteins and discuss novel approaches for combination treatments with novel immunomodulatory agents.作者: sinoatrial-node 時間: 2025-3-25 21:15
Managing Regulatory T Cells to Improve Cancer Immunotherapyunctional blockade, differentiation blockade, altering trafficking, differentiation diversion, or raising the threshold of anti-cancer effector cells for Treg-mediated regulation. Several clinical trials have shown the feasibility and relative safety of managing Tregs in human cancer, although treat作者: hemophilia 時間: 2025-3-26 01:43
T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment. In this chapter, we review and summarize current knowledge regarding the function, interactions, and prognostic significance of each of these populations, as well as their dependence upon one another within the tumor microenvironment.作者: Benzodiazepines 時間: 2025-3-26 07:36 作者: 笨拙的你 時間: 2025-3-26 12:07
International Political Economy Series. In this chapter, we review and summarize current knowledge regarding the function, interactions, and prognostic significance of each of these populations, as well as their dependence upon one another within the tumor microenvironment.作者: impale 時間: 2025-3-26 13:24 作者: 運動吧 時間: 2025-3-26 18:28 作者: 緯線 時間: 2025-3-26 21:45 作者: opprobrious 時間: 2025-3-27 02:29
https://doi.org/10.1007/978-88-470-2571-4igrate to the draining lymph nodes where they can induce an antigen-specific T cell response. A promising strategy to induce a potent, specific, and lasting anti-tumor response is to target tumor antigens to DC in vivo. This represents a clinically generally applicable and cost-effective approach to作者: 騙子 時間: 2025-3-27 07:48 作者: Anticonvulsants 時間: 2025-3-27 12:55 作者: 陰險 時間: 2025-3-27 14:37 作者: Analogy 時間: 2025-3-27 19:19 作者: 陶醉 時間: 2025-3-27 22:53 作者: 事先無準備 時間: 2025-3-28 05:21
Giorgio Uboldi,Giorgio Cavigliaal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This作者: 專心 時間: 2025-3-28 09:10
A Process Dedicated to Cognition and Memorydes a broad overview of additional approaches not covered in specific book chapters. Some areas are nonetheless quite advanced, such as the use of TLR agonists in clinical trials, and some have received FDA approvals such as BCG to treat bladder cancer and the IMiD lenalidomide to treat multiple mye作者: 忍耐 時間: 2025-3-28 13:13
The New Aesthetic of Data Narrativeative parameters of immune function affords the opportunity to identify endpoints that correlate with, or predict clinical benefit and define the requirements for effective therapy. This chapter discusses structural and functional methods to assess both monoclonal and polyclonal antigen-specific T c作者: Supplement 時間: 2025-3-28 16:04 作者: Creditee 時間: 2025-3-28 19:01 作者: 神秘 時間: 2025-3-29 00:20 作者: 空洞 時間: 2025-3-29 06:24 作者: 本能 時間: 2025-3-29 10:43 作者: faddish 時間: 2025-3-29 13:48 作者: CLOUT 時間: 2025-3-29 16:18
International Political Economy Series. In this chapter, we review and summarize current knowledge regarding the function, interactions, and prognostic significance of each of these populations, as well as their dependence upon one another within the tumor microenvironment.作者: libertine 時間: 2025-3-29 20:13 作者: Sigmoidoscopy 時間: 2025-3-30 03:31
https://doi.org/10.1007/978-88-470-2571-4 the production of various intermediates such as reactive nitrogen species and reactive oxygen species that can suppress T cell function. Here, we review recent concepts on how MDSC can regulate T cell function in cancer and other chronic inflammatory diseases and suggest possible therapeutic interventions to overcome this inhibitory effect.作者: 遍及 時間: 2025-3-30 07:45
Cytokines in the Treatment of Cancerdels. New strategies for improving the therapeutic benefit of cytokines are in development and include cytokine-antibody fusion molecules, delivery in recombinant viral vectors, expression by irradiated whole tumor cells, PEGylation, DNA vaccination, and ex vivo exposure to immune effector cells.作者: medieval 時間: 2025-3-30 11:10
Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives the production of various intermediates such as reactive nitrogen species and reactive oxygen species that can suppress T cell function. Here, we review recent concepts on how MDSC can regulate T cell function in cancer and other chronic inflammatory diseases and suggest possible therapeutic interventions to overcome this inhibitory effect.作者: 空氣傳播 時間: 2025-3-30 13:18 作者: Root494 時間: 2025-3-30 19:56
